Amgen (0R0T) AI Stock Analysis

Amgen

(LSE:0R0T)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diversified Revenue GrowthBroad growth across major products reduces reliance on a single therapy and shows that Amgen’s commercial momentum is supported by a diversified portfolio. Continued expansion across multiple franchises can improve revenue durability and help offset individual product maturation.

Negative Factors

High LeverageAmgen’s sizable debt burden reduces financial flexibility and makes the business more sensitive to refinancing costs or a downturn in earnings. Although leverage has improved from prior years, obligations remain high relative to equity and could constrain future capital allocation.

Amgen (0R0T) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $251.94B
Dividend Yield: 2.12%
Average Volume (3M): 2,097
Price to Earnings (P/E): 28.7
Beta (1Y): 0.64
Revenue Growth: 9.89%
EPS Growth: 31.69%
Country: UK
Employees: 31,500
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Amgen Business Overview & Revenue Model

Company Description

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span...

Amgen Earnings Call Summary

Earnings Call Date:Aug 03, 2026(Q2-2026)|% Change Since:20.87%|Next Earnings Date:Nov 02, 2026

Earnings Call SentimentPositive

The call reported broad-based commercial strength (10% revenue growth, multiple products with double-digit increases, raised full-year guidance), robust margins (48% non-GAAP operating margin) and strong cash generation, while also flagging expected near-term expense increases, higher cost-of-sales pressure from mix and profit-share, a material decline in the Prolia/XGEVA franchise (–33%), and some pipeline uncertainty/readouts pending. On balance the positive commercial execution, raised guidance and pipeline momentum outweigh the noted headwinds.

Positive Updates

Strong Revenue Growth

Total revenues exceeded $10.0 billion in Q2, representing a 10% year-over-year increase; 17 products annualized at more than $1 billion based on Q2 sales and 22 products delivered double-digit sales growth.

Negative Updates

Decline in Prolia and XGEVA Sales

Prolia and XGEVA combined sales decreased 33% year-over-year to $1.1 billion, consistent with expectations following the launch of several biosimilar competitors.

Company Guidance

Amgen raised its 2026 guidance, now expecting total revenues of $38.2–$39.4 billion and non‑GAAP EPS of $22.30–$23.50, with other revenue ~ $1.9 billion and non‑GAAP other income/expense of $2.1–$2.2 billion of expense; full‑year non‑GAAP R&D is expected to grow high‑single digits (Q2 R&D was +10% YoY) and a $100 million upfront BD payment will boost Q3 R&D, while capital expenditures are forecast at ≈$2.6 billion for 2026 (Q2 capex was $500 million) to scale manufacturing for volume growth; management expects a full‑year non‑GAAP operating margin of roughly 45–46% of product sales (Q2 non‑GAAP operating margin was 48%, with Q2 cost of sales 19.6% of product sales), generated $3.5 billion of free cash flow in Q2, raised the quarterly dividend to $2.52/share (+6% YoY), expects a non‑GAAP tax rate of 15.0–16.5%, anticipates a meaningful sequential increase in operating expenses in Q3, and plans share repurchases not to exceed $3 billion.

Amgen Risk Analysis

Amgen disclosed 28 risk factors in its most recent earnings report. Amgen reported the most risks in the "Ability to Sell" category.

Ability to Sell - Risks related to the company’s ability to sell goods and services

Latest Risks Added

0 New Risks

Amgen Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0R0T against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABBV	72Outperform	$521.11B	83.08	-223.75%	2.35%	10.68%	―
NVS	72Outperform	$297.25B	31.19	24.24%	2.95%	1.64%	-28.72%
JNJ	70Outperform	$657.68B	41.42	19.55%	1.93%	7.81%	-35.95%
BMY	66Neutral	$127.71B	13.82	43.88%	4.03%	4.19%	52.55%
MRK	63Neutral	$368.89B	152.57	5.10%	2.27%	5.16%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GB:0R0T and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0R0T	Amgen Inc	466.85	179.65	62.55%
BMY	Bristol-Myers Squibb Company	62.48	18.42	41.81%
JNJ	Johnson & Johnson	273.20	91.04	49.98%
MRK	Merck & Company	149.52	69.38	86.58%
NVS	Novartis AG	160.79	39.31	32.36%
ABBV	Abbvie	294.89	89.09	43.29%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Amgen AI Stock Analysis